ONMD OneMedNet Corp Insider Trading

ONMD CEO Aaron Green buys 36,650 shares at $0.57, third ONMD purchase in 11 days; 2 other insiders also bought within past 14 days

Aaron Green, Chief Executive Officer of OneMedNet Corp (ONMD), purchased 36,650 shares at $0.57 on 2026-06-23, bringing his post-transaction holdings to 1,896,375 shares — his third open-market buy at ONMD in 11 days, following prior purchases on 2026-06-12 and 2026-06-15. This purchase occurs with the stock down -85.8% from its 52-week high and -33.6% over the past 30 days. The cluster pattern is notable: 2 other insiders also bought within the past 14 days, making this part of a broader accumulation trend among company insiders. The company carries a quarterly net income of $-2,453,000.00 against revenue of $96,000.00, with a market cap of $32,660,044.20, providing context for the scale of these purchases relative to the company's financial position.

CMO Jeff Yu buys 158,730 shares at $0.63; stock down 85.8% from $4.22 high; 2 other insiders bought in past 14 days

Jeffrey Yu, Chief Medical Officer, purchased 158,730 shares at $0.63 on 2026-06-23, bringing holdings to 8,780,410 shares, as ONMD trades at $0.60—down 85.8% from its 52-week high of $4.22. This buy arrives amid severe recent price deterioration (−33.6% over 30 days, −30.7% over 90 days) and follows a cluster pattern: 2 other insiders also bought within the past 14 days. Yu's prior trades at this ticker show 3 of 3 prior buys were well-timed at the 90-day mark, with gains of +128.2%, +130.4%, and +151.6% on those respective purchases. However, the company's fundamentals remain pressured—latest quarter revenue was $96,000 ($96.0K), net income −$2,453,000 (−$2.5M), and the firm was unprofitable over its most recent full fiscal year despite annual revenue growth of +111.4%. The insider's demonstrated precision on prior ONMD trades and the multi-insider buy pattern warrant observation, though the stock's acute drawdown from its 52-week peak and persistent negative earnings create substantial uncertainty about the market's current pricing.

CMO Jeffrey Yu bought 172,414 shares of ONMD at $0.58; stock now $0.50. Cluster buy with 2 other insiders in 14 days, but stock down 88.2% from 52-week high.

Jeffrey Yu, Chief Medical Officer, purchased 172,414 shares at $0.58 on 2026-06-16 as part of a cluster buy pattern (2 other insiders also bought within 14 days). His prior trades at ONMD show a pattern of well-timed entries: 4 of 4 prior buys achieved positive 90-day returns (range +26.5% to +50.5%). However, the current market context is severely adverse—the stock is trading at $0.50, down 88.2% from its 52-week high of $4.22, down 40.6% in 30 days, and down 39.0% in 90 days. The company remains unprofitable ($-2.5M net income) despite 111.4% annual revenue growth, with a market cap of $27.2M. The timing signal from prior ONMD buys is not yet clear for this transaction, as the 90-day outcome is unmeasurable. Cluster activity combined with historical pattern warrants monitoring, but the severe price deterioration and persistent unprofitability present material offsetting risks.

CEO Aaron Green bought 55,622 shares of ONMD in 2 transactions for $30,696.65 at $0.55 avg; stock down 87.2% from 52-week high.

Aaron Green, CEO of OneMedNet Corp, executed 2 separate open-market purchases totaling 55,622 shares for $30,696.65, increasing his holdings by 3.1% from 1,804,103 to 1,859,725 shares. The purchases occurred at $0.56 on 2026-06-12 and $0.54 on 2026-06-15, with a blended average price of $0.55—close to the current price of $0.54. The timing is notable given severe recent price deterioration: the stock is down 87.2% from its 52-week high of $4.22 and down 42.0% over the past 30 days. The company is unprofitable (latest quarter: net income of $-2,453,000.00) despite strong annual revenue growth of 111.4%, indicating operational losses even as top-line expands. The CEO's direct capital commitment at depressed price levels, combined with a $29.4M market cap and significant operational losses, represents material insider accumulation at a juncture of pronounced equity deterioration.

Director Thomas Kosasa buys 158.7K ONMD shares at $0.63; stock down 42.0% in 30 days, near 52-week lows

Thomas Kosasa purchased 158,730 shares at $0.63 on 2026-06-12, expanding his holdings to 17.09M shares (+0.9%). The transaction occurs in the context of severe recent price deterioration: the stock has fallen 42.0% over 30 days and trades at $0.54, representing a decline of 87.2% from its 52-week high of $4.22. At the same-ticker level, Kosasa's prior three completed ONMD buys all showed positive 90-day returns, with a timing pattern of 3 of 3 well-timed at the 90-day mark, though his most recent same-ticker purchase on 2026-05-18 and 2026-04-23 remain too recent for 90-day measurement. The underlying company presents fundamental headwinds: latest quarterly revenue was $96.0K, the firm generated a net loss of $2.5M, and despite annual revenue growth of 111.4%, the company remains unprofitable. This buy-on-weakness action by a substantial shareholder (now holding 17.09M shares) occurs as the stock approaches multi-year lows, but the timing signal is complicated by both the current downtrend and the immature revenue base relative to operating losses.

Director Kosasa Thomas buys 268,817 shares of ONMD at $0.93 for $249,999.81; stock now $0.87, -79.4% from 52-week high.

Kosasa Thomas, a director, purchased 268,817 shares at $0.93 on 2026-05-18, increasing holdings from 16,661,327 to 16,930,144 shares. The current price of $0.87 reflects a -7.0% decline over 30 days and positions the stock -79.4% below its 52-week high of $4.22. At the same-ticker level, Thomas's 5 prior purchases at ONMD show outcomes ranging from -19.0% to +151.8% in the first 30 days and -12.0% to +112.0% over 90 days, with 4 of 5 prior buys showing positive 90-day returns. The company's fundamentals are marked by significant unprofitability (net income of $-2,453,000.00 in the latest quarter, unprofitable full year) despite strong annual revenue growth of +111.4%. This buy occurs as the stock has recovered +28.6% over 90 days from recent lows but remains severely depressed relative to recent highs, warranting scrutiny of whether this accumulation reflects conviction or other factors in a micro-cap, loss-making business.

ONMD Chief Medical Officer bought 903,614 shares at $0.83 for $750.0K, extending prior pattern: 5 of 5 recent purchases at this ticker well-timed post-trade.

Yu Jeffrey, Chief Medical Officer, purchased 903,614 shares at $0.83 on 2026-04-01, increasing his holdings to 8.45M shares (+12.0%). This transaction is noteworthy because his prior trading history at OneMedNet—five consecutive purchases made in September 2025—all delivered positive 90-day returns, ranging from +26.5% to +50.5%, indicating consistent timing success at this specific ticker. His cross-ticker track record reinforces this pattern, with 95.00% of his 20 prior open-market buys producing positive 90-day returns and an average 90-day return of +64.7%. The current market price of $1.10 is +27.1% above his April transaction price in the 30-day window, aligning with his historical performance. However, the company remains fundamentally challenged: it posted a quarterly revenue of $177.0K, a net loss of $-741.0K, and unprofitable full-year results, despite strong annual revenue growth of +111.4%. The timing signal is clear, but underlying profitability remains a material concern for investors.

Director Kosasa Thomas purchased 876,136 shares across 2 tranches ($750.0K) at $0.84–$0.89; 5 of 5 prior ONMD buys achieved positive 90-day returns (38.2%–120.7%).

Director Kosasa Thomas completed 2 separate purchases totaling 876,136 shares for $749,999.14 at blended average price $0.86, increasing his holdings to 16.66M shares (+5.6%). His track record at ONMD is notably consistent: all 5 prior open-market buys at this ticker achieved positive 90-day returns ranging from 38.2% to 120.7%, with the most recent buy on 2025-09-24 returning +151.8% over 30 days. The current stock price of $1.10 is down 65.0% from the 52-week high of $3.14 but up 27.1% in the last 30 days and 12.2% over 90 days, placing this purchase in a period of recent momentum recovery. Against this backdrop of repeated well-timed accumulation at the same ticker, the filing signals continued conviction in the name after a steep drawdown from peak valuations.

CFO Golden Robert Lawrence bought 300 ONMD shares at $1.71 (Dec 2023); stock now $1.42 (-37.7% in 30 days)

Golden Robert Lawrence, CFO of OneMedNet Corp, purchased 300 shares at $1.71 on 2023-12-07, a modest $513.00 acquisition that increased his holdings from 547,605 to 547,905 shares (+0.1%). The company is financially distressed: latest quarterly revenue is $177.0K with net income of $-741.0K, annual revenue contracted -37.0%, and the firm is unprofitable on a full-year basis. The stock has deteriorated sharply, down -37.7% in the 30 days since the purchase and trading -54.8% below its 52-week high of $3.14. An insider equity purchase during such severe operational and stock-price distress warrants scrutiny given the company's inability to generate positive earnings and declining top-line trajectory.

Director Kosasa Thomas bought 1,879,871 shares for $1,049,474.52 across 5 transactions (avg $0.56); now holds 15,785,191 shares post-transaction.

Kosasa Thomas, a Director at OneMedNet Corp, executed five separate purchases totaling 1,879,871 shares (1.88M shares) for $1,049,474.52 between April and September 2025 at prices ranging from $0.38 to $0.93, with a blended average of $0.56. His holdings increased by 13.5% to 15,785,191 shares post-transaction. This accumulation occurs against a backdrop of significant financial deterioration: the company reported $177,000.00 in latest quarterly revenue with a net loss of $-741,000.00, annual revenue has declined 37.0%, and the stock has fallen 54.8% from its 52-week high and 37.7% over the past 30 days. The current stock price of $1.42 stands well above the blended transaction price of $0.56, suggesting the insider was purchasing at meaningfully depressed levels relative to recent valuations. The concentration of purchases and the accumulation pattern merit scrutiny given the company's unprofitability and deteriorating financial metrics.